中国人群卵巢癌患者一级亲属卵巢癌风险评估工具的开发与验证
本研究建立双向多中心队列,纳入529例先证者和3141名一级亲属,用标准化发病比(SIR)分析癌症发生率,经Cox回归构建列线图并以C指数评价模型。1596名女性一级亲属中识别57例卵巢癌,SIR=9.19(95%CI 7.03-11.83,p<0.001);列线图C指数训练集0.75、内部验证0.75、外部验证0.71,以10%癌症风险为阈值划分高低危组,cut-off值2.1。
要点
- 女性一级亲属卵巢癌SIR=9.19(95%CI 7.03-11.83,p<0.001)。
- 胚系突变亲属卵巢癌SIR=23.33、乳腺癌SIR=3.56。
- 列线图C指数训练集0.75、内部验证0.75、外部验证0.71。
核心结论
- 本研究开发并初步验证了针对中国卵巢癌患者一级亲属的风险评估工具,利用可获得的临床与家族数据早期识别高危个体。
研究设计与样本
- 建立双向多中心队列,纳入529例先证者和3141名一级亲属。
- 采用标准化发病比(SIR)分析癌症发生率,通过Cox回归识别显著变量并绘制列线图。
- 以C指数评价模型性能,按10%癌症风险阈值将一级亲属分为高危组和低危组。
主要发现
- 1596名女性一级亲属中识别57例卵巢癌,SIR=9.19(95%CI 7.03-11.83,p<0.001)。
- 980名胚系突变亲属中卵巢癌SIR=23.33(95%CI 16.51-32.09,p<0.001),乳腺癌SIR=3.56(95%CI 2.46-5.00,p<0.001)。
- Cox回归识别关键风险因素包括先证者发病年龄、肿瘤组织学、基因突变状态、乳腺癌家族史及与先证者的关系。
- 列线图C指数训练集0.75、内部验证0.75、外部验证0.71,校准曲线和Kaplan-Meier曲线显示高低危组间一致性好且差异显著(cut-off值=2.1)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To develop and validate an ovarian cancer risk assessment tool for first-degree relatives of patients in the Chinese population. METHODS: A bidirectional multicenter cohort was established, including 529 probands and 3141 first-degree relatives. Cancer incidence was analyzed using the standardized incidence ratio (SIR). Significant variables were identified through Cox regression analyses and visualized via a nomogram. Model performance was evaluated using the C-index, with first-degree relatives stratified into high- and low-risk groups based on a 10 % cancer risk threshold. RESULTS: Among 1596 first-degree female relatives, 57 ovarian cancer cases were identified, demonstrating a significant increase in SIR (SIR = 9.19; 95 % CI, 7.03-11.83; p < 0.001). In 980 relatives with germline mutations, elevated SIRs were observed for ovarian cancer (SIR = 23.33; 95 % CI, 16.51-32.09; p < 0.001) and breast cancer (SIR = 3.56; 95 % CI, 2.46-5.00; p < 0.001). Cox regression analyses identified key risk factors, including the proband's age of onset, tumor histology, gene mutation status, family history of breast cancer, and relationship to the proband. The nomogram demonstrated good predictive accuracy, with C-indices of 0.75 (training set), 0.75 (internal validation), and 0.71 (external validation). Calibration plots and Kaplan-Meier curves confirmed strong agreement and significant differences between high- and low-risk groups (cut-off value = 2.1). CONCLUSIONS: This study develops and preliminarily validates a risk assessment tool for first-degree relatives of ovarian cancer patients in China, utilizing accessible clinical and familial data to enable early identification of high-risk individuals.
引用
- Li Y, Wu M, Liu Q, et al. Development and validation of an ovarian cancer risk assessment tool for first-degree relatives of patients in the Chinese population. Gynecol Oncol. 2025. PMID: 40117943. doi:10.1016/j.ygyno.2025.03.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。